Amarin Corp Plc (AMRN)

[Jeffkad]

G, if I’m understanding your numbers, it would appear that even at your lowest estimate of $1200/680, a BO at or slightly above the current market cap could be justified by just Europe market peak rev. Assumption is that EU/all Europe population is 500M/750M, so not impossible to grab at least 4-5M V patients. So if AMRN loses patent case, an interesting stock play could emerge: the share price will undoubtedly dive, and in these type scenarios, typically well below a rationale bottom. Buying this massive drop would likely afford a pretty nice round trip back to (or at least near) current price once market reevaluates and realizes Europe potential (not to mention Asia) and more important, the remaining BO potential (as you identify in your post). I still wonder what, if any, US revenue potential would remain, or is there no chance to compete with the generic makers?